Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.

Oncogene - 15 Sept 2005

Croonquist Paula A, Van Ness Brian

Abstract excerpt

Three distinct proliferative signals for multiple myeloma (MM) cell lines induce enhancer of zeste homolog 2 (ezh 2) transcript expression. EZH 2 is a polycomb group protein that mediates repression of gene transcription at the chromatin level through its methyltransferase activity. Normal bone marrow plasma cells do not express ezh2; however, gene expression is induced and correlates with tumor burden during...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalysis
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Interleukin-6

Share to Mice, Nude

Share to Multiple Myeloma

Share to NIH 3T3 Cells

Share to Polycomb Repressive Complex 2

Source

Identifiers

PMID: 16007202
DOI: 10.1038/sj.onc.1208771

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.PMID 16007202Read ↗

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].Semantic proximity Read ↗

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myelomaSemantic proximity Read ↗

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.Semantic proximity Read ↗

Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2Semantic proximity Read ↗

Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell LineSemantic proximity Read ↗

Loss of the SMRT/NCoR2 Corepressor Correlates with JAG2 Overexpression in Multiple MyelomaSemantic proximity Read ↗

Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma TherapySemantic proximity Read ↗

Effects of rearrangement and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival.Semantic proximity Read ↗

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast DifferentiationSemantic proximity Read ↗

The polycomb group protein EZH2 is involved in progression of prostate cancer.Semantic proximity Read ↗

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destructionSemantic proximity Read ↗

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.